Lymphoma

Experts map DLBCL CAR‑T from early referral and bridging therapy to managing CRS, ICANS, and survivorship challenges in community practice.

Guilherme Fleury Perini, MD, PhD, discussed KEYFORM-008 findings on favezelimab/pembrolizumab vs chemotherapy in PD-1–refractory classic Hodgkin lymphoma.

Findings from the phase 2 MOR208C203 trial and phase 1b/2 INCMOR 0208-102 trial support the Japanese regulatory decision for tafasitamab in DLBCL.

“I love that our field is taking an ambitious swing at how best to take care of patients who are older and less fit with large cell lymphoma,” said Matthew Matasar, MD, chief in the division of Blood Disorders, Rutgers Cancer Institute/Jack & Sheryl Morris Cancer Center, and professor of medicine at Rutgers Robert Wood Johnson Medical School.

Findings from the phase 3 SUNMO trial support the regulatory decision regarding the mosunetuzumab-based regimen for this relapsed/refractory population.

The investigators concluded that the impact of autologous stem cell transplantation with ibrutinib cannot be determined vs ibrutinib alone.

Among 3-to-25-year-old patients with slow, early responses to chemotherapy with newly diagnosed classic Hodgkin lymphoma, pembrolizumab showed an ORR of 98%.

Emmanuel Bachy, MD, PhD, shared data from a phase 1b study evaluating subcutaneous mosunetuzumab plus lenalidomide in untreated follicular lymphoma.

Brentuximab vedotin plus ifosfamide, carboplatin, and etoposide conferred significantly increased toxicity vs 2 other chemotherapy-containing regimens.

Updated phase 1/1b BGB-11417-101 trial data showed sonrotoclax 320 mg plus zanubrutinib achieved uMRD4 rates exceeding 90% in treatment-naive CLL/SLL.

Emmanuel Bachy, MD, PhD, highlighted high efficacy, durable responses, and a favorable adverse effect profile in follicular lymphoma with high tumor burden.

The safety profile of the CAR T-cell product in the real world was consistent with that observed in the TRANSCEND MCL study.

No new safety signals were observed with the LAG-3 inhibitor-based therapy among patients with relapsed/refractory classic Hodgkin lymphoma.

The brentuximab vedotin-based regimen was consistently favored in sensitivity analyses regardless of covariate adjustment tested.

The use of CD20×CD3 bispecific antibodies correlated with lower hematologic toxicity, higher responses, and preserved CAR T fitness in LBCL groups.

The phase 3 EPCORE DLBCL-1 data showed epcoritamab reduced progression or death risk by 26% vs chemoimmunotherapy in relapsed/refractory LBCL.

There was no clear prognostic impact of age, comorbidities, complex living skills, or basic self-care tasks on PFS for diffuse large B-cell lymphoma.

The addition of epcoritamab to lenalidomide and rituximab showed improved efficacy and manageable safety in relapsed/refractory follicular lymphoma.

Adverse drug reactions occurred in 1 patient treated with VT-EBV-N, although no grade 3 or higher events emerged.

Support for the NMPA approval of rocbrutinib in relapsed/refractory mantle cell lymphoma was based on findings from the phase 2 ROCK-1 trial.

No dose-limiting toxicities, TEAE-related discontinuations, or deaths were observed in this pretreated lymphoma population.

In those with centrally confirmed lymphoma subtypes, the HR for PFS was 0.68, with a 24-month PFS rate of 72.7% vs 62.2% in favor of the tafasitamab combo.

Matthew Matasar, MD, of Rutgers Cancer Institute, spoke about upcoming trials in lymphoma to look out for at the ASCO 2026 Meeting.

Orelabrutinib is now available in Australia for patients with relapsed/refractory mantle cell lymphoma.

Clinician-rated toxicities appear to consistently underreport severity compared with patient-reported outcomes in this lymphoma population.